Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of VSA006 in Chinese adults with nonalcoholic steatohepatitis
CTR20233245Phase 2Active
- Sponsor
- Visirna Therapeutics
- Start
- Apr 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of GSK4532990 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Visirna Therapeutics. Started Apr 2024; status: active.
02
Drugs
GSK4532990
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20233245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233245.